Health Condition 1: D570- Hb-SS disease with crisis
Conditions
Interventions
Intervention1: Continuous Intravenous Infusion versus Intermittent Intramuscular Injection of Tramadol: 1.intravenous continuous infusion of tramadol dose- 0.25mg/kg/hr.
2.intramuscular intermittent t
Sponsors
VIMSAR
Eligibility
Inclusion criteria
Inclusion criteria: 1-diagnosed case of sickle cell disease with vaso-occlusive crisis both homozygous and compound hetrerozygous(by HPLC study) 2-VOC will be diagnosed if the patient present with pain involving skeleton, chest, abdomen or all three lasting 4hours or more. 3-moderate to severe grade of VOC (VISUAL ANALOGUE SCALE)
Exclusion criteria
Exclusion criteria: 1- cases associated with diabetes mellitus, stroke, peripheral vascular disease, polycythemia that are likely to modify viscosity of blood. 2- contraindication for tramadol. 3- critically ill patients including acute chest syndrome.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Study may throw light on efficacy of continuous intravenous of tramadol for the treatment of vaso-occlusive crises in sickle cell disease patients.Timepoint: 1year 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-onset of pain relief 2- breakthrough pain 3- use of adjuvant 4- adverse effect 5- degree/ duration of pain relief 6- cumulative dose since pain reliefTimepoint: 1 year 6 months | — |
Countries
India
Contacts
Public ContactDR BALADEV PRASAD KAR
VSS Institute of Medical Science & Research
Outcome results
None listed